RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 146 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.32 and the average weighting 2.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,665,076 | +2.4% | 217,657 | 0.0% | 0.37% | +1.9% |
Q2 2023 | $1,625,898 | +12.0% | 217,657 | 0.0% | 0.36% | -1.9% |
Q1 2023 | $1,451,772 | -13.5% | 217,657 | 0.0% | 0.37% | -17.9% |
Q4 2022 | $1,678,135 | -27.5% | 217,657 | 0.0% | 0.45% | -27.5% |
Q3 2022 | $2,316,000 | +30.7% | 217,657 | 0.0% | 0.62% | +38.9% |
Q2 2022 | $1,772,000 | +13.7% | 217,657 | 0.0% | 0.44% | +61.8% |
Q1 2022 | $1,559,000 | -58.2% | 217,657 | 0.0% | 0.28% | -46.9% |
Q4 2021 | $3,729,000 | +138.0% | 217,657 | +219.6% | 0.52% | +113.2% |
Q3 2021 | $1,567,000 | -37.0% | 68,104 | 0.0% | 0.24% | -43.1% |
Q2 2021 | $2,486,000 | – | 68,104 | – | 0.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |